ISPOR - PGI15 COST-UTILITY AND BUDGET IMPACT ANALYSES OF INFLIXIMAB AND ITS BIOSIMILAR IN THAI PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE

PGI15 COST-UTILITY AND BUDGET IMPACT ANALYSES OF INFLIXIMAB AND ITS BIOSIMILAR IN THAI PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE

Abstract

Authors

P. Phisalprapa C. Kositamongkol N. Chaiyakunapruk

Full Text Cite This Article

Back to Volume 22, Supplemental S3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now